Dialysis industry news

Stories from the dialysis comunity across the globe.



Young cries foul on health service decision - Cowra Guardian PDF Print

Cowra Health Service management are expected to meet with the Young Health Advisory Committee in coming weeks to alleviate concerns over renal services in the region.

Young cries foul on health service decision - Cowra Guardian

Cowra mayor Cr Bill West with a copy of the Young Witness, which mobilised the public to protest against the decision by the NSW State Government to install a satellite renal unit in Cowra, not Young.

Young cries foul on health service decision - Cowra Guardian

Cowra mayor Cr Bill West with a copy of the Young Witness, which mobilised the public to protest against the decision by the NSW State Government to install a satellite renal unit in Cowra, not Young.

Young cries foul on health service decision - Cowra Guardian

Cowra mayor Cr Bill West with a copy of the Young Witness, which mobilised the public to protest against the decision by the NSW State Government to install a satellite renal unit in Cowra, not Young.

Cowra Health Service management are expected to meet with the Young Health Advisory Committee in coming weeks to alleviate concerns over renal services in the region.

A petition circulating in Young, Harden and Boorowa is railing against the state government's decision not to install a satellite-managed renal unit in Young.

Instead, the Murrumbidgee Local Health District, which includes the three towns, announced a partnership with the Western NSW Local Health District earlier this month so their patients will be able to access the eight-chair renal unit when it becomes operational in early 2016.

This partnership would complement the community-funded renal service already operating in the town, which allows people to self-administer dialysis.

But Young Shire Councillors reacted violently to the announcement, with Cr Stuart Freudenstein asking whether they should be "knocking doors down to express their disappointment".

Cowra Health Service manager Pauline Rowston still hopes a representative from Young will become involved in the ongoing development of the Cowra renal unit.

She said in Cowra, there are six people currently travelling to other facilities for treatment, with a further 14 people currently on the pre-dialysis database.

"[This] demonstrates a strong need for a local service which can also treat patients from nearby towns," Ms Rowston said.

"We look forward to providing renal treatment services in Cowra to our neighbours from Young so that they no longer need to travel a further distance to Canberra."

Cowra mayor, Cr Bill West agreed with Ms Rowston, saying the renal unit will be an important addition to the chemotherapy and ambulatory care units at Cowra hospital.

He said he was unsure what commitments had been made to Young, but believed the people weren't saying they did not want Cowra to receive a unit.

"Our unit will benefit people in the broader region including Young," Cr West said.

"I can understand [Young's] disappointment but how they fund units is a matter for the relevant health bodies. I hope Young are not seeking a renal unit at the expense of Cowra."

Murrumbidgee Local Health District's (MLHD) executive director of nursing and midwifery Karen Cairney said the combined activity from both Cowra and Young would assist with the sustainability of the Cowra renal service

She said access to Cowra's unit will significantly cut travel times for Young patients driving more than two hours, three times a week to Canberra or Queanbeyan.

"Due to the location of the towns, it is logical for both LHDs to partner up and provide this service to the whole community in the region," she said.

"The eight bed renal unit in Cowra, along with the self-care renal unit based in Young, provides a great outcome for patients across the local area."

Member for Cootamundra Katrina Hodgkinson said she believed the Murrumbidgee Local Health District has looked at the feasibility of establishing a renal care centre in Young.

She said she was hopeful they would continue exploring this concept.

"With an hour drive ahead of them, I know the journey from Young to Cowra may not always be convenient; but it means Young patients will no longer have to continue travelling for two hours to Canberra or Queanbeyan for treatment," Ms Hodgkinson said.

"Looking at the demand for dialysis in the region generally, Cowra was the most logical, convenient location given current demand, allowing fairer access and reduced travel time to more patients across our broader region."

She added changes to the Isolated Patient Travel and Accommodation Assistance Scheme will mean patients travelling 200 kilometres a week cumulatively can claim 22 cents per litre of fuel as of September - an increase from the current 19 cents per litre.

Construction will begin on the Cowra renal unit in July.

...

 
IgG4-related kidney disease from the renal pelvis that mimicked urothelial ... - BMC Blogs Network PDF Print

IgG4-RKD is a comprehensive term for renal lesions, including renal parenchymal lesions and renal pelvic lesions, related to IgG4-RD, which is a recently recognized and proposed clinical entity characterized by a dense lymphoplasmacytic infiltrate rich in IgG4+ plasma cells with fibrosis that affects several organs [6], [9]. TIN involving tubules and/or the interstitium of the kidney is the most dominant feature of IgG4-RKD [9]; however, IgG4-RKD in the renal pelvis is rare [7]–[10]. Here, we report a rare case of IgG4-RKD that mimicked renal pelvic carcinoma.

A comprehensive English and non-English search for all articles pertinent to IgG4-RD of the renal pelvis was conducted using PubMed. Since Naoto Kuroda [11] first reported a case of IgG4-RD arising in the renal pelvis in 2009, six cases of IgG4-RD of the renal pelvis have been reported previously in the world literature (Table 1) [12]–[16]. The mean age at diagnosis was 59.8 years (range: 49 to 80 years), with a male: female ratio of 1:1. Most patients presented with renal lesions in the left kidney, with a left-to-right presentation ratio of 2:1. Patients visited the hospital with or without complaints of non-characteristic presentations (i.e., flank pain), and none of the patients had hematuria. Hypocomplementemia and elevated serum IgG are characteristic features of IgG4-RD. Elevated serum IgG and IgG4 were found in all patients, but no hypocomplementemia was found in these seven cases, including our case (Table 1). Although hypocomplementemia is a distinct feature of IgG4-RD, a relatively low proportion of patients actually have it.

Table 1. Previous reports of IgG4-related kidney disease arising in the renal pelvis

Patients with IgG4-RD often have lesions in several organs, either synchronously or metachronously, although others may show the involvement of only a single organ. Renal lesions are recognized as extra-pancreatic manifestations of IgG4-RD; the condition can develop as IgG4-RKD singly or associated with the lesions of other organs. In previous cases, renal and extra-renal (salivary gland) involvements in IgG4-RD have presented simultaneously in two patients [11], [12]. In the current case, a systemic examination showed no other abnormal findings, inclusive of the salivary glands, lacrimal glands, and pancreas. Thus, the condition was diagnosed as IgG4-RD isolated in the renal pelvis without the involvement of other organs.

On the basis of the results of a diagnostic algorithm procedure and with references to several diagnostic criteria for AIP, Mitsuhiro Kawano [6] proposed diagnostic criteria for IgG4-RKD: (1) presence of some kidney damage, as manifested by laboratory examination; (2) kidney imaging studies showing abnormal renal findings, i.e., multiple low-density lesions on enhanced CT; (3) elevated serum IgG4 levels exceeding 135 mg/dL; (4) renal histology showing dense lymphoplasmacytic infiltration with infiltrating IgG4+ plasma cells and fibrosis; and (5) extra-renal histology showing prominent lymphoplasmacytic infiltration with infiltrating IgG4+ plasma cells. The diagnosis is classified into three stages—definite, probable, and possible—according to the combinations of the above conditions. In their diagnostic criteria, abnormal renal imaging findings were essential for making a definitive diagnosis. In the present case, all of these conditions, including imaging studies that identified low-density lesions, pathologic examinations that revealed characteristic changes, and elevated serum IgG4, prompted the definitive diagnosis of IgG4-RKD.

A rapid response to corticosteroid therapy is a characteristic feature of IgG4-RD, and corticosteroids are typically the first line of therapy, although no controlled trial has been performed. Moreover, the protocol used for corticosteroid therapy varies among countries and institutions [1]. Because of the decreased level of serum IgG4 after ureteronephrectomy, our patient received a close follow-up without corticosteroid therapy. In the reported cases, patients with IgG4-RKD arising from the renal pelvis were treated according to different strategies, including surgical treatment alone for two patients, corticosteroid therapy alone for two patients, and surgical and corticosteroid treatment for the remaining two patients. The renal lesions improved or resolved after the corticosteroid treatment in three patients who received corticosteroid treatment (Table 1). Takahashi and colleagues [17] also found that lesions progressed in three IgG4-TIN patients receiving no corticosteroid treatment or surgical resection and that lesions regressed in all IgG4-TIN patients who underwent corticosteroid treatment. These observations indicate that effective interventions should begin as soon as possible for irreversible fibrosis in IgG4-RKD. Because corticosteroid treatment has a remarkable effect in this type of disease, at least in the short term, this treatment is vital to avoid unnecessary surgery. CT-guided biopsy or laparoscopic biopsy of the original tumor might help to rule out malignancy.

Recent studies have revealed several characteristic clinical features of IgG4-RKD, including predominance in middle-aged to older men, frequent association with IgG4-RD in other organs, high levels of serum IgG and IgG4, and a good initial response to corticosteroids. However, longer follow-up data for IgG4-RKD, including relapse information, are still sparse. Takako Saeki and his colleagues [18] retrospectively analyzed the longer-term clinical course of 43 patients with IgG4-TIN in detail in a larger cohort. This analysis included the largest series on the long-term outcomes of corticosteroid treatment of IgG4-RKD. Saeki et al. showed that 1 month after the start of treatment, most of the abnormal serology and radiology parameters had improved, and relapse of IgG4-related lesions occurred in 8 of 40 treated patients. These studies indicate that the response of IgG4-RKD to corticosteroids is rapid and partial, and that irreversible lesions may remain, especially in patients with advanced renal damage. Patients with renal dysfunction should receive corticosteroid therapy, although spontaneous improvement of lesions can also occur in IgG4-TIN and the indications for corticosteroid therapy in IgG4-RKD have not been established. Careful attention should be paid to renal function during follow-up without therapy [18], [19]. A large-scale prospective study is necessary to determine a more useful treatment strategy for IgG4-RKD.

...

 
DSI Renal opens 100th dialysis clinic - NephrologyNews.com PDF Print

Dialysis provider DSI Renal has opened their 100th dialysis clinic, located in Travelers Rest, S.C.

“We are excited about opening our 100th clinic and for the effort that it represents. It is tangible evidence of what we have accomplished to date,” said Craig Goguen, president and CEO of DSI Renal. “This is an important milestone for our company and physician partners. It further recognizes the dedication of an entire team and the trust that our physician partners have put in us to achieve such great success in a short time.”

DSI formed in late 2011 with the acquisition of 30 dialysis.  The company now has dialysis clinics in 22 states.

“This time last year we had 90 locations, today we are at 100 locations, and we plan to exceed 110 by year end,” said Goguen. “We are planning to add 15-20 clinics per year, and that doesn’t include any acquisition opportunities that present themselves.”

The Travelers Rest dialysis clinic is the 7th DSI location in South Carolina.

...

 
Emma Ugolee: Former TV host petitions health ministry for subsidised cost of ... - Pulse Nigeria PDF Print

Former television host, Emma Ugolee who is himself a kidney transplant survivor has petitioned the minister of health and the law makers of the house of assembly for a subsidised cost of dialysis treatment.

Ugolee launched a petition on change.org which has so far garnered over 2,419 supporters.

Read Emma's appeal on the petition below:

Hey there,

Over 20million Nigerians are affected by kidney disease? as direct victims and tens of millions more as their friends and family. Diabetes and High blood pressure are the leading causes of kidney disease.

Patients of chronic kidney disease stage 5 would die in a few weeks without a treatment called dialysis. Dialysis in Nigeria cost about N480,000 a month (N40,000 a session) at the required 3 sessions per week. This is not the case in Sudan and Namibiawhere government subsidised the cost. Ivory Coast gives free dialysis to her citizens.

Being that those that cannot afford dialysis simply DIE!!! As they do daily, does this not directly violate ?our basic HUMAN RIGHT to health? which also re-emphasises our right to EXIST or RIGHT TO LIFE?

My name is Emmanuel U?golee, I have the Chronic kidney disease and know very personally the pain of the helpless and voiceless millions suffering from this emotional, physical and financial burden of this disease on whose behalf I seek for your simple signature on this appeal to the minister of health and law makers of the national assembly to consider subsidising dialysis. We need half a million signatures. Kindly make yours count.

...

 
Non-Dialysis CKD-MBD Care Suboptimal - Renal and Urology News PDF Print
May 26, 2015 Non-Dialysis CKD-MBD Care Suboptimal - Renal and Urology News
Therapeutic inertia was 34% at 6 months. It was defined as lack of prescriptions despite hyperphosphatemia, hypocalcemia, and/or hyperparathyroidism.

A significant proportion of non-dialysis chronic kidney disease (CKD) patients have inadequately managed mineral bone density (MBD), according to a new Italian study. Therapeutic inertia appears to be a barrier to good care of these patients, researchers concluded.

For the study, Maurizio Gallieni, MD, of the Nephrology and Dialysis Unit, Ospedale San Carlo A10 Borromeo, University of Milan, and colleagues prospectively evaluated CKD-MBD management in 727 non-dialysis, Caucasian patients over 2 visits occurring 6 months apart. All patients had 1 or more markers of MBD, including hyperphosphatemia, hypocalcemia, and/or hyperparathyroidism, and all were considered compliant with prescribed therapy.

According to results published online ahead of print in the Journal of Nephrology, more than 65% of the patients did not reach parathyroid hormone (PTH) targets, 19% missed calcium targets, and 15% missed phosphate targets. Each of the 19 nephrology clinics involved in the study had their own clinical targets, although most generally followed Kidney Disease Outcomes Quality Initiative (KDOQI) recommendations.

The prevalence of therapeutic inertia was 34% at 6 months. It was defined as lack of phosphate binder prescriptions despite hyperphosphatemia; lack of calcium and vitamin D supplements despite hypocalcemia; or lack of phosphate binders and calcium and vitamin D supplements despite hyperparathyroidism.

Therapeutic inertia was highest for hyperphosphatemia at 54%. For example, 51% of the 212 patients with serum phosphate greater than 4.1 mg/dL received neither phosphate binders nor a prescription for a low-protein diet. PTH was off-target in two-thirds of patients.

“This significant difference between PTH and phosphate-calcium control in the follow-up of our cohort is likely the consequences of early onset of PTH elevation in the course of CKD,” the researchers wrote.

The likelihood of inadequate treatment overall decreased as CKD worsened to stages 4 and 5 (by 40% and 68%, respectively).

The management of CKD-MBD in non-dialysis patients appears subpar, especially compared with the care of dialysis patients. The impetus for CKD-MBD prescriptions appeared to be worsening renal function rather than test results assessing each mineral. 

Source

  1. Gallieni, M, et al. Journal of Nephrology; doi: 10.1007/s40620-015-0202-4.

...

 
<< Start < Prev 201 202 203 204 205 206 207 208 209 210 Next > End >>

Page 209 of 4210
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.